VetDC achieves key regulatory milestone, nears FDA approval of TANOVEA™-CA1 for Canine Lymphoma

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., a veterinary cancer therapeutics company, today announced that the Company has received three major technical section complete letters for TANOVEA™-CA1 (rabacfosadine) from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (FDA-CVM). Upon approval, … Keep Reading